Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Reply to comment on: The diagnostic accuracy and clinical utility of pediatric renal tumor biopsy: Report of the UK experience in the SIOP UK WT2001 trial.

Brisse H, de La Monneraye Y, Schleiermacher G.

Pediatr Blood Cancer. 2019 Aug;66(8):e27828. doi: 10.1002/pbc.27828. Epub 2019 May 21. No abstract available.

PMID:
31115131
2.

Study of chromatin remodeling genes implicates SMARCA4 as a putative player in oncogenesis in neuroblastoma.

Bellini A, Bessoltane-Bentahar N, Bhalshankar J, Clement N, Raynal V, Baulande S, Bernard V, Danzon A, Chicard M, Colmet-Daage L, Pierron G, Le Roux L, Planchon JM, Combaret V, Lapouble E, Corradini N, Thebaud E, Gambart M, Valteau-Couanet D, Michon J, Louis-Brennetot C, Janoueix-Lerosey I, Defachelles AS, Bourdeaut F, Delattre O, Schleiermacher G.

Int J Cancer. 2019 Apr 24. doi: 10.1002/ijc.32361. [Epub ahead of print]

PMID:
31018240
3.

Indications and results of diagnostic biopsy in pediatric renal tumors: A retrospective analysis of 317 patients with critical review of SIOP guidelines.

de la Monneraye Y, Michon J, Pacquement H, Aerts I, Orbach D, Doz F, Bourdeaut F, Sarnacki S, Philippe-Chomette P, Audry G, Coulomb A, Fréneaux P, Klijanienko J, Berrebi D, Zucker JM, Schleiermacher G, Brisse HJ.

Pediatr Blood Cancer. 2019 Jun;66(6):e27641. doi: 10.1002/pbc.27641. Epub 2019 Feb 12.

PMID:
30746839
4.

Parental smoking, maternal alcohol consumption during pregnancy and the risk of neuroblastoma in children. A pooled analysis of the ESCALE and ESTELLE French studies.

Rios P, Bailey HD, Poulalhon C, Valteau-Couanet D, Schleiermacher G, Bergeron C, Petit A, Defachelles AS, Marion G, Sirvent N, Ducassou S, Munzer C, Orsi L, Lacour B, Clavel J.

Int J Cancer. 2019 Jan 29. doi: 10.1002/ijc.32161. [Epub ahead of print]

PMID:
30697705
5.

Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients.

Zeka F, Decock A, Van Goethem A, Vanderheyden K, Demuynck F, Lammens T, Helsmoortel HH, Vermeulen J, Noguera R, Berbegall AP, Combaret V, Schleiermacher G, Laureys G, Schramm A, Schulte JH, Rahmann S, Bienertová-Vašků J, Mazánek P, Jeison M, Ash S, Hogarty MD, Moreno-Smith M, Barbieri E, Shohet J, Berthold F, Van Maerken T, Speleman F, Fischer M, De Preter K, Mestdagh P, Vandesompele J.

JCI Insight. 2018 Dec 6;3(23). pii: 97021. doi: 10.1172/jci.insight.97021.

6.

The challenge of defining "ultra-high-risk" neuroblastoma.

Morgenstern DA, Bagatell R, Cohn SL, Hogarty MD, Maris JM, Moreno L, Park JR, Pearson AD, Schleiermacher G, Valteau-Couanet D, London WB, Irwin MS.

Pediatr Blood Cancer. 2019 Apr;66(4):e27556. doi: 10.1002/pbc.27556. Epub 2018 Nov 26. Review.

PMID:
30479064
7.

TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets.

Decaesteker B, Denecker G, Van Neste C, Dolman EM, Van Loocke W, Gartlgruber M, Nunes C, De Vloed F, Depuydt P, Verboom K, Rombaut D, Loontiens S, De Wyn J, Kholosy WM, Koopmans B, Essing AHW, Herrmann C, Dreidax D, Durinck K, Deforce D, van Nieuwerburgh F, Henssen A, Versteeg R, Boeva V, Schleiermacher G, van Nes J, Mestdagh P, Vanhauwaert S, Schulte JH, Westermann F, Molenaar JJ, De Preter K, Speleman F.

Nat Commun. 2018 Nov 19;9(1):4866. doi: 10.1038/s41467-018-06699-9.

8.

Meta-mining of copy number profiles of high-risk neuroblastoma tumors.

Depuydt P, Koster J, Boeva V, Hocking TD, Speleman F, Schleiermacher G, De Preter K.

Sci Data. 2018 Oct 30;5:180240. doi: 10.1038/sdata.2018.240.

9.

[High-risk neuroblastoma treatment strategy: The experience of the SIOPEN group].

Valteau-Couanet D, Schleiermacher G, Sarnacki S, Pasqualini C.

Bull Cancer. 2018 Oct;105(10):918-924. doi: 10.1016/j.bulcan.2018.09.002. Epub 2018 Oct 2. Review. French.

PMID:
30290975
10.

Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN study.

Morgenstern DA, Pötschger U, Moreno L, Papadakis V, Owens C, Ash S, Pasqualini C, Luksch R, Garaventa A, Canete A, Elliot M, Wieczorek A, Laureys G, Kogner P, Malis J, Ruud E, Beck-Popovic M, Schleiermacher G, Valteau-Couanet D, Ladenstein R.

Pediatr Blood Cancer. 2018 Nov;65(11):e27363. doi: 10.1002/pbc.27363. Epub 2018 Jul 17.

PMID:
30015396
11.

Circulating tumor DNA analysis enables molecular characterization of pediatric renal tumors at diagnosis.

Jiménez I, Chicard M, Colmet-Daage L, Clément N, Danzon A, Lapouble E, Pierron G, Bohec M, Baulande S, Berrebi D, Fréneaux P, Coulomb A, Galmiche-Rolland L, Sarnacki S, Audry G, Philippe-Chomette P, Brisse HJ, Doz F, Michon J, Delattre O, Schleiermacher G.

Int J Cancer. 2019 Jan 1;144(1):68-79. doi: 10.1002/ijc.31620. Epub 2018 Oct 26.

PMID:
29923174
12.

Feasibility of Busulfan Melphalan and Stem Cell Rescue After 131I-MIBG and Topotecan Therapy for Refractory or Relapsed Metastatic Neuroblastoma: The French Experience.

Ferry I, Kolesnikov-Gauthier H, Oudoux A, Cougnenc O, Schleiermacher G, Michon J, Bogart E, Chastagner P, Proust S, Valteau-Couanet D, Defachelles AS.

J Pediatr Hematol Oncol. 2018 Aug;40(6):426-432. doi: 10.1097/MPH.0000000000001137.

PMID:
29642099
13.

Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut Curie.

Basse C, Morel C, Alt M, Sablin MP, Franck C, Pierron G, Callens C, Melaabi S, Masliah-Planchon J, Bataillon G, Gardrat S, Lavigne M, Bonsang B, Vaflard P, Pons Tostivint E, Dubot C, Loirat D, Marous M, Geiss R, Clément N, Schleiermacher G, Kamoun C, Girard E, Ardin M, Benoist C, Bernard V, Mariani O, Rouzier R, Tresca P, Servois V, Vincent-Salomon A, Bieche I, Le Tourneau C, Kamal M.

ESMO Open. 2018 Apr 6;3(3):e000339. doi: 10.1136/esmoopen-2018-000339. eCollection 2018.

14.

Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.

Depuydt P, Boeva V, Hocking TD, Cannoodt R, Ambros IM, Ambros PF, Asgharzadeh S, Attiyeh EF, Combaret V, Defferrari R, Fischer M, Hero B, Hogarty MD, Irwin MS, Koster J, Kreissman S, Ladenstein R, Lapouble E, Laureys G, London WB, Mazzocco K, Nakagawara A, Noguera R, Ohira M, Park JR, Pötschger U, Theissen J, Tonini GP, Valteau-Couanet D, Varesio L, Versteeg R, Speleman F, Maris JM, Schleiermacher G, De Preter K.

J Natl Cancer Inst. 2018 Oct 1;110(10):1084-1093. doi: 10.1093/jnci/djy022.

15.

Prognostic impact of postoperative 123I-metaiodobenzylguanidine scintigraphy: added value of SPECT/CT and semiquantification of the uptake at the surgical site.

Gauthé M, Breton M, Jehanno N, Cellier C, Michon J, Sarnacki S, Schleiermacher G, Wartski M.

Q J Nucl Med Mol Imaging. 2018 Feb 5. doi: 10.23736/S1824-4785.18.03031-5. [Epub ahead of print]

PMID:
29409315
16.

QuantumClone: clonal assessment of functional mutations in cancer based on a genotype-aware method for clonal reconstruction.

Deveau P, Colmet Daage L, Oldridge D, Bernard V, Bellini A, Chicard M, Clement N, Lapouble E, Combaret V, Boland A, Meyer V, Deleuze JF, Janoueix-Lerosey I, Barillot E, Delattre O, Maris JM, Schleiermacher G, Boeva V.

Bioinformatics. 2018 Jun 1;34(11):1808-1816. doi: 10.1093/bioinformatics/bty016.

17.

Enrollment in early-phase clinical trials in pediatric oncology: The experience at Institut Curie.

Surun A, Dujaric MÉ, Aerts I, Orbach D, Jiménez I, Pacquement H, Schleiermacher G, Bourdeaut F, Michon J, Dupont JK, Doz F.

Pediatr Blood Cancer. 2018 May;65(5):e26916. doi: 10.1002/pbc.26916. Epub 2018 Jan 15.

PMID:
29334194
18.

Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma.

Chicard M, Colmet-Daage L, Clement N, Danzon A, Bohec M, Bernard V, Baulande S, Bellini A, Deveau P, Pierron G, Lapouble E, Janoueix-Lerosey I, Peuchmaur M, Corradini N, Defachelles AS, Valteau-Couanet D, Michon J, Combaret V, Delattre O, Schleiermacher G.

Clin Cancer Res. 2018 Feb 15;24(4):939-949. doi: 10.1158/1078-0432.CCR-17-1586. Epub 2017 Nov 30.

19.

Genomic Profiles of Neuroblastoma Associated With Opsoclonus Myoclonus Syndrome.

Hero B, Clement N, Øra I, Pierron G, Lapouble E, Theissen J, Pasqualini C, Valteau-Couanet D, Plantaz D, Michon J, Delattre O, Tardieu M, Schleiermacher G.

J Pediatr Hematol Oncol. 2018 Mar;40(2):93-98. doi: 10.1097/MPH.0000000000000976.

PMID:
29135842
20.

Radiogenomics of neuroblastomas: Relationships between imaging phenotypes, tumor genomic profile and survival.

Brisse HJ, Blanc T, Schleiermacher G, Mosseri V, Philippe-Chomette P, Janoueix-Lerosey I, Pierron G, Lapouble E, Peuchmaur M, Fréneaux P, Galmiche L, Algret N, Peycelon M, Michon J, Delattre O, Sarnacki S.

PLoS One. 2017 Sep 25;12(9):e0185190. doi: 10.1371/journal.pone.0185190. eCollection 2017.

21.

Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries.

Boeva V, Louis-Brennetot C, Peltier A, Durand S, Pierre-Eugène C, Raynal V, Etchevers HC, Thomas S, Lermine A, Daudigeos-Dubus E, Geoerger B, Orth MF, Grünewald TGP, Diaz E, Ducos B, Surdez D, Carcaboso AM, Medvedeva I, Deller T, Combaret V, Lapouble E, Pierron G, Grossetête-Lalami S, Baulande S, Schleiermacher G, Barillot E, Rohrer H, Delattre O, Janoueix-Lerosey I.

Nat Genet. 2017 Sep;49(9):1408-1413. doi: 10.1038/ng.3921. Epub 2017 Jul 24.

PMID:
28740262
22.

From class waivers to precision medicine in paediatric oncology.

Pearson ADJ, Pfister SM, Baruchel A, Bourquin JP, Casanova M, Chesler L, Doz F, Eggert A, Geoerger B, Jones DTW, Kearns PR, Molenaar JJ, Morland B, Schleiermacher G, Schulte JH, Vormoor J, Marshall LV, Zwaan CM, Vassal G; Executive and Biology Committees of the Innovative Therapies for Children with Cancer European Consortium.

Lancet Oncol. 2017 Jul;18(7):e394-e404. doi: 10.1016/S1470-2045(17)30442-4. Review.

PMID:
28677575
23.

Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project.

Moreno L, Caron H, Geoerger B, Eggert A, Schleiermacher G, Brock P, Valteau-Couanet D, Chesler L, Schulte JH, De Preter K, Molenaar J, Schramm A, Eilers M, Van Maerken T, Johnsen JI, Garrett M, George SL, Tweddle DA, Kogner P, Berthold F, Koster J, Barone G, Tucker ER, Marshall L, Herold R, Sterba J, Norga K, Vassal G, Pearson AD.

Expert Opin Drug Discov. 2017 Aug;12(8):801-811. doi: 10.1080/17460441.2017.1340269. Epub 2017 Jun 26. Review.

PMID:
28604107
24.

Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.

Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, Burchill S, Boubaker A, McHugh K, Nuchtern JG, London WB, Seibel NL, Lindwasser OW, Maris JM, Brock P, Schleiermacher G, Ladenstein R, Matthay KK, Valteau-Couanet D.

J Clin Oncol. 2017 Aug 1;35(22):2580-2587. doi: 10.1200/JCO.2016.72.0177. Epub 2017 May 4. Review.

25.

Long-term results of the transmanubrial osteomuscular-sparing approach for pediatric tumors.

El Madi A, Irtan S, Sauvat F, Zérah M, Schleiermacher G, Galmiche-Roland L, Minard-Colin V, Brisse H, Sarnacki S.

Pediatr Blood Cancer. 2017 Oct;64(10). doi: 10.1002/pbc.26527. Epub 2017 Apr 14.

PMID:
28409885
26.

Pediatric Patient With Renal Cell Carcinoma Treated by Successive Antiangiogenics Drugs: A Case Report and Review of the Literature.

Jiménez I, Brisse HJ, Fréneaux P, Sarnacki S, Michon J, Orbach D, Pierron G, Clément N, Doz F, Escudier B, Schleiermacher G.

J Pediatr Hematol Oncol. 2017 Jul;39(5):e279-e284. doi: 10.1097/MPH.0000000000000774.

PMID:
28338568
27.

Kids Enter the MATCH.

Schleiermacher G, Delattre O.

J Natl Cancer Inst. 2016 Dec 31;109(5). doi: 10.1093/jnci/djw305. Print 2017 May. No abstract available.

PMID:
28040695
28.

Feasibility and clinical integration of molecular profiling for target identification in pediatric solid tumors.

Pincez T, Clément N, Lapouble E, Pierron G, Kamal M, Bieche I, Bernard V, Fréneaux P, Michon J, Orbach D, Aerts I, Pacquement H, Bourdeaut F, Jiménez I, Thébaud E, Oudot C, Vérité C, Taque S, Owens C, Doz F, Le Tourneau C, Delattre O, Schleiermacher G.

Pediatr Blood Cancer. 2017 Jun;64(6). doi: 10.1002/pbc.26365. Epub 2016 Nov 29.

PMID:
27896933
29.

Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse.

Chen L, Humphreys A, Turnbull L, Bellini A, Schleiermacher G, Salwen H, Cohn SL, Bown N, Tweddle DA.

Oncotarget. 2016 Dec 27;7(52):87301-87311. doi: 10.18632/oncotarget.13541.

30.

Neuroblastoma.

Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, Weiss WA.

Nat Rev Dis Primers. 2016 Nov 10;2:16078. doi: 10.1038/nrdp.2016.78. Review.

PMID:
27830764
31.

IT Infrastructure for Merging Data from Different Clinical Trials and Across Independent Research Networks.

Hayn D, Falgenhauer M, Kropf M, Nitzlnader M, Welte S, Ebner H, Ladenstein R, Schleiermacher G, Hero B, Schreier G.

Stud Health Technol Inform. 2016;228:287-91.

PMID:
27577389
32.

A Dilated Cardiomyopathy Revealing a Neuroblastoma: Which Link?

Duhil de Bénazé G, Iserin F, Durand P, Schleiermacher G, Orbach D.

J Pediatr Hematol Oncol. 2016 Oct;38(7):e251-3. doi: 10.1097/MPH.0000000000000659.

PMID:
27571126
33.

Genomic Copy Number Profiling Using Circulating Free Tumor DNA Highlights Heterogeneity in Neuroblastoma.

Chicard M, Boyault S, Colmet Daage L, Richer W, Gentien D, Pierron G, Lapouble E, Bellini A, Clement N, Iacono I, Bréjon S, Carrere M, Reyes C, Hocking T, Bernard V, Peuchmaur M, Corradini N, Faure-Conter C, Coze C, Plantaz D, Defachelles AS, Thebaud E, Gambart M, Millot F, Valteau-Couanet D, Michon J, Puisieux A, Delattre O, Combaret V, Schleiermacher G.

Clin Cancer Res. 2016 Nov 15;22(22):5564-5573. doi: 10.1158/1078-0432.CCR-16-0500. Epub 2016 Jul 20.

34.

Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database.

Morgenstern DA, London WB, Stephens D, Volchenboum SL, Simon T, Nakagawara A, Shimada H, Schleiermacher G, Matthay KK, Cohn SL, Pearson AD, Irwin MS.

Eur J Cancer. 2016 Sep;65:1-10. doi: 10.1016/j.ejca.2016.06.005. Epub 2016 Jul 17.

PMID:
27434878
35.

Implementation of mechanism of action biology-driven early drug development for children with cancer.

Pearson AD, Herold R, Rousseau R, Copland C, Bradley-Garelik B, Binner D, Capdeville R, Caron H, Carleer J, Chesler L, Geoerger B, Kearns P, Marshall LV, Pfister SM, Schleiermacher G, Skolnik J, Spadoni C, Sterba J, van den Berg H, Uttenreuther-Fischer M, Witt O, Norga K, Vassal G; Members of Working Group 1 of the Paediatric Platform of ACCELERATE.

Eur J Cancer. 2016 Jul;62:124-31. doi: 10.1016/j.ejca.2016.04.001. Epub 2016 May 31. Review.

PMID:
27258969
36.

Is Nephron Sparing Surgery Justified in Wilms Tumor With Beckwith-Wiedemann Syndrome or Isolated Hemihypertrophy?

Scalabre A, Bergeron C, Brioude F, Dainese L, Cropet C, Coulomb L'hermine A, Pasqualini C, Auber F, Verschuur A, Schleiermacher G, Le Bouc Y, Audry G, Irtan S.

Pediatr Blood Cancer. 2016 Sep;63(9):1571-7. doi: 10.1002/pbc.26073. Epub 2016 May 27.

PMID:
27228957
37.

Piloting the European Unified Patient Identity Management (EUPID) Concept to Facilitate Secondary Use of Neuroblastoma Data from Clinical Trials and Biobanking.

Ebner H, Hayn D, Falgenhauer M, Nitzlnader M, Schleiermacher G, Haupt R, Erminio G, Defferrari R, Mazzocco K, Kohler J, Tonini GP, Ladenstein R, Schreier G.

Stud Health Technol Inform. 2016;223:31-8.

PMID:
27139382
38.

Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence.

Pinto N, Mayfield JR, Raca G, Applebaum MA, Chlenski A, Sukhanova M, Bagatell R, Irwin MS, Little A, Rawwas J, Gosiengfiao Y, Delattre O, Janoueix-Lerosey I, Lapouble E, Schleiermacher G, Cohn SL.

Pediatr Blood Cancer. 2016 Jun;63(6):1019-23. doi: 10.1002/pbc.25934. Epub 2016 Feb 10.

39.

Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma.

Decock A, Ongenaert M, Cannoodt R, Verniers K, De Wilde B, Laureys G, Van Roy N, Berbegall AP, Bienertova-Vasku J, Bown N, Clément N, Combaret V, Haber M, Hoyoux C, Murray J, Noguera R, Pierron G, Schleiermacher G, Schulte JH, Stallings RL, Tweddle DA; Children’s Cancer and Leukaemia Group (CCLG), De Preter K, Speleman F, Vandesompele J.

Oncotarget. 2016 Jan 12;7(2):1960-72. doi: 10.18632/oncotarget.6477.

40.

Percutaneous Computed Tomography-Guided Thermal Ablation of Pulmonary Osteosarcoma Metastases in Children.

Yevich S, Gaspar N, Tselikas L, Brugières L, Pacquement H, Schleiermacher G, Tabone MD, Pearson E, Canale S, Muret J, de Baere T, Deschamps F.

Ann Surg Oncol. 2016 Apr;23(4):1380-6. doi: 10.1245/s10434-015-4988-z. Epub 2015 Nov 20.

PMID:
26589502
41.

Oncologic Phenotype of Peripheral Neuroblastic Tumors Associated With PHOX2B Non-Polyalanine Repeat Expansion Mutations.

Heide S, Masliah-Planchon J, Isidor B, Guimier A, Bodet D, Coze C, Deville A, Thebault E, Pasquier CJ, Cassagnau E, Pierron G, Clément N, Schleiermacher G, Amiel J, Delattre O, Peuchmaur M, Bourdeaut F.

Pediatr Blood Cancer. 2016 Jan;63(1):71-7. doi: 10.1002/pbc.25723. Epub 2015 Sep 16.

PMID:
26375764
42.

Advances in Risk Classification and Treatment Strategies for Neuroblastoma.

Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, Nakagawara A, Berthold F, Schleiermacher G, Park JR, Valteau-Couanet D, Pearson AD, Cohn SL.

J Clin Oncol. 2015 Sep 20;33(27):3008-17. doi: 10.1200/JCO.2014.59.4648. Epub 2015 Aug 24. Review.

43.

Bone Vertebrae Metastases With Spinal Cord Compression: A Rare Event in Wilms Tumor.

Sudour-Bonnange H, Leblond P, Cellier C, Vinchon M, Lervat C, Rocourt N, Schleiermacher G.

J Pediatr Hematol Oncol. 2015 Aug;37(6):e387-9. doi: 10.1097/MPH.0000000000000332.

PMID:
26186400
44.

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations.

Eleveld TF, Oldridge DA, Bernard V, Koster J, Colmet Daage L, Diskin SJ, Schild L, Bentahar NB, Bellini A, Chicard M, Lapouble E, Combaret V, Legoix-Né P, Michon J, Pugh TJ, Hart LS, Rader J, Attiyeh EF, Wei JS, Zhang S, Naranjo A, Gastier-Foster JM, Hogarty MD, Asgharzadeh S, Smith MA, Guidry Auvil JM, Watkins TB, Zwijnenburg DA, Ebus ME, van Sluis P, Hakkert A, van Wezel E, van der Schoot CE, Westerhout EM, Schulte JH, Tytgat GA, Dolman ME, Janoueix-Lerosey I, Gerhard DS, Caron HN, Delattre O, Khan J, Versteeg R, Schleiermacher G, Molenaar JJ, Maris JM.

Nat Genet. 2015 Aug;47(8):864-71. doi: 10.1038/ng.3333. Epub 2015 Jun 29.

45.

Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis.

Bellini A, Bernard V, Leroy Q, Rio Frio T, Pierron G, Combaret V, Lapouble E, Clement N, Rubie H, Thebaud E, Chastagner P, Defachelles AS, Bergeron C, Buchbinder N, Taque S, Auvrignon A, Valteau-Couanet D, Michon J, Janoueix-Lerosey I, Delattre O, Schleiermacher G.

Clin Cancer Res. 2015 Nov 1;21(21):4913-21. doi: 10.1158/1078-0432.CCR-15-0423. Epub 2015 Jun 9.

46.

Long-term side effects of radiotherapy for pediatric localized neuroblastoma : results from clinical trials NB90 and NB94.

Ducassou A, Gambart M, Munzer C, Padovani L, Carrie C, Haas-Kogan D, Bernier-Chastagner V, Demoor C, Claude L, Helfre S, Bolle S, Leseur J, Huchet A, Rubie H, Valteau-Couanet D, Schleiermacher G, Coze C, Defachelles AS, Marabelle A, Ducassou S, Devalck C, Gandemer V, Munzer M, Laprie A; Neuroblastoma study group and radiotherapy group of the French Society of Children with Cancer (SFCE).

Strahlenther Onkol. 2015 Jul;191(7):604-12. doi: 10.1007/s00066-015-0837-z. Epub 2015 Apr 21.

PMID:
25896312
47.

Image-defined risk factor assessment of neurogenic tumors after neoadjuvant chemotherapy is useful for predicting intra-operative risk factors and the completeness of resection.

Irtan S, Brisse HJ, Minard-Colin V, Schleiermacher G, Galmiche-Rolland L, Le Cossec C, Elie C, Canale S, Michon J, Valteau-Couanet D, Sarnacki S.

Pediatr Blood Cancer. 2015 Sep;62(9):1543-9. doi: 10.1002/pbc.25511. Epub 2015 Mar 27.

PMID:
25820608
48.

Detection of tumor ALK status in neuroblastoma patients using peripheral blood.

Combaret V, Iacono I, Bellini A, Bréjon S, Bernard V, Marabelle A, Coze C, Pierron G, Lapouble E, Schleiermacher G, Blay JY.

Cancer Med. 2015 Apr;4(4):540-50. doi: 10.1002/cam4.414. Epub 2015 Feb 4. Erratum in: Cancer Med. 2016 Feb;5(2):386.

49.

Minimally invasive surgery of neuroblastic tumors in children: Indications depend on anatomical location and image-defined risk factors.

Irtan S, Brisse HJ, Minard-Colin V, Schleiermacher G, Canale S, Sarnacki S.

Pediatr Blood Cancer. 2015 Feb;62(2):257-261. doi: 10.1002/pbc.25248. Epub 2014 Oct 4.

PMID:
25284263
50.

Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification.

Defferrari R, Mazzocco K, Ambros IM, Ambros PF, Bedwell C, Beiske K, Bénard J, Berbegall AP, Bown N, Combaret V, Couturier J, Erminio G, Gambini C, Garaventa A, Gross N, Haupt R, Kohler J, Jeison M, Lunec J, Marques B, Martinsson T, Noguera R, Parodi S, Schleiermacher G, Tweddle DA, Valent A, Van Roy N, Vicha A, Villamon E, Tonini GP.

Br J Cancer. 2015 Jan 20;112(2):290-5. doi: 10.1038/bjc.2014.557. Epub 2014 Nov 4.

Supplemental Content

Loading ...
Support Center